CYP2G2P is pseudogenized in humans because of two nonsense mutations (c.76C>T in exon 1 and c.382C>T in exon 3) in the putative coding region of the gene sequence, whereas mouse, rat, and rabbit CYP2Gs are expressed and functional in nasal mucosa. In this study, we assessed the intactness of CYP2G in a cynomolgus monkey, a macaque species important for drug metabolism studies because of its evolutionary closeness to human. On the basis of a gene sequence (highly identical to human CYP2G2P) found in the macaque genome, CYP2G2 cDNA was successfully isolated from cynomolgus monkey nasal mucosa. CYP2G2 cDNA, containing an open reading frame of 494 amino acids, was shown to share high sequence identity (nearly 95%) with the putative coding region of human CYP2G2P. Cynomolgus monkey CYP2G2 shared the highest sequence identity (59-61%) with CYP2A23, CYP2A24, and CYP2A26 among cynomolgus monkey cytochromes P450. Cynomolgus monkey CYP2G2 mRNA was predominantly expressed in the nasal mucosa, where CYP2G2 protein expression was also detected. Metabolic assays indicated that cynomolgus monkey CYP2G2 metabolized coumarin, similar to cynomolgus monkey CYP2A23, CYP2A24, and CYP2A26. Moreover, among 39 cynomolgus monkeys and 11 rhesus monkeys examined in this study, only 2 cynomolgus monkeys and 1 rhesus monkey were heterozygous for c.76C>T. No animals carried c.382C>T. These results suggest that cynomolgus monkey CYP2G2 is a functional drug-metabolizing enzyme in nasal mucosa.
Introduction
The cytochrome P450 (P450) superfamily contains a large number of genes for drug-metabolizing enzymes, 57 functional genes, and 58 pseudogenes in human (see http://drnelson.uthsc.edu/cytochromeP450.html). CYP2Gs, located in the CYP2ABFGST gene cluster of genomes, were present in mammalian species such as mouse and human (Nelson et al., 2004) . Most CYP2Gs, including human CYP2G2P, however, were pseudogenized during evolution, except for mouse, rat, and rabbit CYP2Gs, which are expressed and encode functional enzymes (Nef et al., 1989; Ding et al., 1991; Hua et al., 1997) . In humans, expression of CYP2G proteins was not detected using rabbit CYP2G antibody (Getchell et al., 1993) , although a partial cDNA, highly identical to CYP2G2P, was isolated (Sheng and Ding, 1996) . Human CYP2G2P contained nonsense mutations in exons 1 and 3 (Sheng et al., 2000) , disrupting the putative open reading frame (ORF), and thus is considered to be a pseudogene.
Mouse CYP2G1 is expressed abundantly in the nasal mucosa and metabolizes sex hormones including testosterone, progesterone, and estradiol (Hua et al., 1997) . Mouse CYP2G1 also plays major roles in metabolism of numerous exogenous substrates such as coumarin, 2,6-dichlorobenzonitrile (herbicide), and acetaminophen Zhuo et al., 1999) , which cause tissue-selective toxicity in the nasal mucosa (Brandt et al., 1990; Gu et al., 1997; Genter et al., 1998) . Likewise, purified rabbit and bovine CYP2G proteins also metabolize these substrates (Ding and Coon, 1994; Longo et al., 1997) . CYP2G might be involved in the cytotoxicity of nasal toxicants in the olfactory chemosensory organ.
In the respiratory tract, nasal mucosa is important as a target for environmental toxicity because of the exposure to both inhaled and blood-borne xenobiotics (Dahl and Hadley, 1991; Ding and Kaminsky, 2003) . Inhalation of, or systemic exposure to industrial chemicals, drugs, chemicals contained in cigarette smoke, and environmental pollutants, has been shown to induce tumors and other toxicities in the nasal mucosa of experimental animals (Dahl and Hadley, 1991; Ding and Kaminsky, 2003) , which could be partly accounted for by drug-metabolizing enzymes in nasal mucosa. Therefore, identification and characterization of such drug-metabolizing enzymes in nasal mucosa are important for understanding the mechanisms of nasal toxicities and for assessing the risk of such toxicities in humans.
Macaques, especially cynomolgus monkey and rhesus monkey, are widely used in drug metabolism studies and toxicity tests because of their evolutionary closeness to humans; however, some differences from humans are occasionally observed in macaques. We previously showed that CYP2C76, not orthologous to any human P450, was partly responsible for the difference in pitavastatin metabolism between cynomolgus monkeys and humans . Such species differences can also be accounted for by macaque P450s orthologous to pseudogenized human P450s including CYP2G2P.
To assess this possibility, in this study, we identified cDNA highly identical to human CYP2G2P in cynomolgus monkey. This cDNA was characterized by sequence and phylogenetic analysis, genomic organization, and drug-metabolizing assays. Moreover, the genomes of cynomolgus monkeys and rhesus monkeys were analyzed for the presence of mutations corresponding to the nonsense mutations in human CYP2G2P.
Materials and Methods
Materials. Oligonucleotides and a fluorescent probe were synthesized by Invitrogen (Tokyo, Japan) and Biosearch Technology Japan (Tokyo, Japan), respectively. Coumarin and all other reagents were purchased from SigmaAldrich (St. Louis, MO) unless otherwise specified.
Tissue Samples and RNA and Genomic DNA Extraction. Total RNA was extracted from brain, lung, heart, liver, kidney, adrenal gland, jejunum, testis, ovary, uterus, and nasal mucosa, which were collected from six cynomolgus monkeys (three males and three females from Indochina, 4 -5 years of age, 3-5 kg), as described previously (Uno et al., 2006) . Genomic DNA was extracted from whole blood samples of 40 cynomolgus monkeys (20 from Indochina and 20 from Indonesia, 4 -5 years of age, 3-5 kg) and 22 rhesus monkeys (from China, 7 years of age, weighing 3-5 kg) using the PUREGENE DNA isolation kit (Gentra Systems, Minneapolis, MN) according to the manufacturer's instructions. This study was reviewed and approved by the Institutional Animal Care and Use Committee at Shin Nippon Biomedical Laboratories Ltd. (Kainan, Japan).
Cloning and Sequencing of CYP2G2 cDNA. Reverse transcription (RT)-polymerase chain reaction (PCR) was performed using total RNA extracted from cynomolgus monkey nasal mucosa as described previously (Uno et al., 2006) . The subsequent PCR was carried out with the generated cDNA as a template using KOD Plus DNA polymerase (Toyobo, Osaka, Japan) according to the manufacturer's protocol with a thermal cycler (Applied Biosystems, Foster City, CA). PCR conditions were an initial denaturation at 95°C for 2 min and 35 cycles of 95°C for 20 s, 58°C for 20 s, and 72°C for 2 min, followed by a final extension at 72°C for 10 min. The primers used were 5Ј-GACCTGGCACCATGGAGAT-3Ј and 5Ј-CCTGAACAcGAGAGGAGAGC-3Ј. These primers were designed to amplify the potential ORF of a gene highly identical to human CYP2G2P found in the rhesus monkey genome data. To verify the translation initiation codon in the cynomolgus monkey CYP2G2 cDNA, 5Ј rapid amplification of cDNA ends (RACE) was carried out with cynomolgus monkey nasal mucosa total RNA using 5Ј-RACE System for Rapid Amplification of cDNA Ends (Invitrogen) according to the manufacturer's protocol. The primers used were as follows: 5Ј-TGACCTTGGAAGTTTC-3Ј for RT reaction, 5Ј-ACTGAACTCATCCGCTTG-GTCT-3Ј for the initial PCR, and 5Ј-CACAGGGCCGTATTTCTCC-3Ј for the nested PCR. After addition of an A-overhang, the PCR products were cloned into pCR2.1 vectors using the TOPO TA Cloning Kit (Invitrogen) according to the manufacturer's protocol. The inserts were sequenced using ABI PRISM BigDye Terminator version 3.0 Ready Reaction Cycle Sequencing Kit (Applied Biosystems), followed by electrophoresis with the ABI PRISM 3730 DNA Analyzer (Applied Biosystems).
Bioinformatics. Sequence analysis was carried out with DNASIS Pro (Hitachi Software, Tokyo, Japan) and the Genetyx system (Software Development, Tokyo, Japan). Multiple alignment of amino acid sequences were carried out using ClustalW, and a phylogenetic tree was created by the neighbor-joining method. A homology search was conducted by Basic Local Alignment Search Tool (BLAST) (National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD). The human and rhesus monkey genome data were analyzed using the BLAST-Like Alignment Tool (BLAT) (UCSC Genome Bioinformatics, Santa Cruz, CA). The P450 amino acid sequences used for the analysis were found in GenBank; human CYP1A1 (NP_000490), CYP2A6 (NP_000753), CYP2A7 (NP_000755), CYP2A13 (NP_000757), CYP2B6 (NP_000758), CYP2C8 (NP_000761), CYP2C9 (NP_000762), CYP2C18 (NP_000763), CYP2C19 (NP_000760), CYP2D6 (NP_000097), CYP2E1 (NP_000764), CYP2F1 (NP_000765), CYP2J2 (NP_000766), CYP2R1 (NP_078790), CYP2S1 (NP_085125), CYP2U1 (NP_898898), and CYP2W1 (NP_060251); and cynomolgus monkey CYP2A23 (AAZ29436), CYP2A24 (AAZ29438), CYP2A26 (ADM53741), CYP2B6 (AAZ29439), CYP2C18 (ABB87194), CYP2C20 (AAB24950), CYP2C43 (AAZ29452), CYP2C75 (AAZ29451), CYP2C76 (AAZ29453), CYP2D17 (AAA79722), CYP2D44 (ABB87193), CYP2E1 (ADM73512), and CYP2J2 (AAZ29440). Cynomolgus monkey CYP2G2 amino acid sequence was deduced from the cDNA identified in this study. Human CYP2G2P amino acid sequence was predicted from its gene sequence found in the human genome.
Real-Time RT-PCR. The expression level of CYP2G2 mRNA was measured in brain, lung, heart, liver, kidney, adrenal gland, jejunum, testis, ovary, uterus, and nasal mucosa and normalized to the 18S ribosomal RNA level, as previously reported (Uno et al., 2006) , with the following modifications. The amplification was carried out with the ABI PRISM 7500 sequence detection system (Applied Biosystems) following the manufacturer's protocol. The primers used were 5Ј-CAGTATTTGCCAGGAAGACACAA-3Ј and 5Ј-GAGGACCAAGTTCTT-GAGGTTGA-3Ј, and the probe used was 5Ј-FAM-CCCAAAACCCTC-GGGACTTCATTG-BHQ-3Ј. A final concentration of the primer set and the probe was 600 and 200 nM, respectively. For each sample, three independent amplifications were performed.
Expression of P450 Proteins. Cynomolgus monkey CYP2A23, CYP2A24, CYP2A26, and CYP2G2 proteins were heterologously expressed in Escherichia coli using expression plasmids as previously described (Iwata et al., 1998; Uno et al., 2006) , with the following modifications. The protein N terminus was modified by PCR using the forward and reverse primers, 5Ј-GGAATTCCATATGGCTCT-GTTATTAGCAGTTTTTATCTTTCTGGCACTCTGCTTGTC-3Ј and 5Ј-GCTCTAGAGCTCAGCGGGCCACGA-3Ј, respectively. The NdeI and XbaI sites (underlined) in the forward and reverse primers, respectively, were used to subclone the amplicons into the pCW vector containing human NADPH-P450 reductase cDNA. For CYP2A23, CYP2A24, and CYP2A26, the expression plasmids were prepared as described previously (Uno et al., 2007; Uehara et al., 2010) . The membrane preparation and measurement of P450 protein and reductase contents in each sample were carried out as described previously (Iwata et al., 1998) .
Enzyme Assays. Metabolic activity of cynomolgus monkey CYP2G2 was measured using coumarin or progesterone as a substrate, as described previously (Yamazaki and Shimada, 1997; Yamazaki et al., 1999) . In brief, a typical incubation mixture (0.25 ml) contained recombinant protein (5 pmol) or microsomal fractions (cynomolgus monkey liver or nasal mucosa, 0.1 mg protein/ml), an NADPH-generating system (0.25 mM NADP ϩ , 2.5 mM glucose 6-phosphate, and 0.25 units/ml glucose 6-phosphate dehydrogenase), and substrate (10 M coumarin or 200 M progesterone) in 100 mM potassium phosphate buffer (pH 7.4). After incubation at 37°C for 10 min, reactions were terminated by addition of 25 l of 60% HClO 4 (w/v) or 0.1 M HCl. Reaction mixtures were centrifuged at 900g for 5 min, and supernatants were analyzed directly or after extraction with ethyl acetate by high-performance liquid chromatography with a fluorescence or an UV detector, respectively.
Western Blot Analysis of CYP2G2 Expression. Preparation of rabbit anti-CYP2G2 antibody and Western blot analysis were performed as previously described (Uno et al., 2006) , with the following modifications. The rabbit anti-CYP2G2 antibody was produced by Thermo Fisher Scientific (Waltham, MA) using specific peptides NH2-YPQHFLDEQGRFKK-COOH. Nasal mucosa microsomes were prepared, and proteins were quantified as described previously (Ding and Coon, 1990) . Cynomolgus monkey CYP2A23, CYP2A24, CYP2A26, and CYP2G2 proteins (1.0 pmol each) and pooled nasal mucosa microsomes (15, 50, and 100 g) were run on 10% SDS polyacrylamide gels and transferred to Hybond-P filters (GE Healthcare, Chalfont St. Giles, UK). The filters were blotted with anti-CYP2G2 antibody (1:1000) or anti-human CYP2A6 antibody (1:100,000; Nosan Corporation, Yokohama, Japan) as the primary antibody, and sheep anti-rabbit IgG was conjugated with horseradish peroxidase (Surmodics, Eden Prairie, MN) as the secondary antibody. CYP2A and CYP2G2 protein bands were visualized using ECL Western blotting detection reagent (GE Healthcare) according to the manufacturer's instruction.
Amplification and Sequencing of CYP2G2 Exons. The human CYP2G2P putative ORF is disrupted by two nonsense mutations (one in exon 1 and one in exon 3). To assess the presence of corresponding mutations in monkeys, exons 1 and 3 from 20 Indochinese and 20 Indonesian cynomolgus monkeys 718 UNO ET AL.
at ASPET Journals on June 21, 2017 dmd.aspetjournals.org as well as 22 Chinese rhesus monkeys were amplified by PCR. Reactions contained 1 ng of genomic DNA, 10 pmol of each primer, 0.2 mM deoxynucleoside-5Ј-triphosphates, 2 mM MgCl 2 , and 1 unit of AmpliTaq Gold (Applied Biosystems) in a total volume of 20 l. PCR was performed for 35 cycles as follows: 94°C for 15 s, 58°C for 30 s, and 72°C for 2 min. The primers used were 5Ј-GCTGAGGCATAAGAATCACC-3Ј and 5Ј-CAG-GCATACAACACTACGCT-3Ј for exon 1 and 5Ј-CATCCCTCCACCTTC-CTATG-3Ј and 5Ј-ACTTTTAATATGGAAGCTGGCC-3Ј for exon 3. The sequence of the PCR product was determined by direct sequencing as described earlier, using the sequencing primers as follows: 5Ј-CTCCAATGA-CATTCAAACCC-3Ј for exon 1 and 5Ј-GATCCTGGAGAGAGGGAACC-3Ј for exon 3.
Results
Molecular Cloning of CYP2G2 cDNA. To isolate cynomolgus monkey CYP2G2 cDNA, RT-PCR was performed with cynomolgus monkey nasal mucosa RNA with gene-specific primers to amplify the potential ORF of cynomolgus monkey CYP2G2. The primers were designed on the basis of a gene sequence, highly identical to human CYP2G2P, in the rhesus monkey genome. The successfully isolated CYP2G2 cDNA contained an ORF of 494 amino acids with primary sequence motifs characteristic of P450 proteins such as the putative substrate recognition sites (Gotoh, 1992) and heme-binding region (Fig. 1) . Because the forward primer used for cloning overlapped with the putative translation initiation codon, 5Ј-RACE was performed with nasal mucosa of cynomolgus monkey to confirm the putative ORF. This analysis extended the 5Ј-untranslated region (UTR) by 389 base pairs (bp) and verified the translation initiation site. The sequence of this CYP2G2 cDNA, including the extended 5Ј-UTR, has been deposited in GenBank under accession number GU289743. The sequence identity of this CYP2G2 cDNA to other P450 nucleotide sequences was determined using BLAST. Cynomolgus monkey CYP2G2 cDNA shared high sequence identity with rhesus monkey CYP2G2 (99%), human CYP2G2P (95%), cattle CYP2G1 (90%), rat CYP2G1 cDNA (82%), and mouse CYP2G1 cDNA (82%) ( Table 1) . Among the cDNA of cynomolgus monkey P450 other than CYP2G, cynomolgus monkey CYP2G2 cDNA shared the highest sequence identity with CYP2A23, CYP2A24, and CYP2A26 cDNA. Phylogenetic analysis of human and cynomolgus monkey CYP2 amino acids showed that cynomolgus monkey CYP2G2 was most closely clustered with human CYP2G2P, indicating the molecular similarity in cynomolgus monkey CYP2G2 and human CYP2G2P (Fig. 2) . In the CYP2 family, the CYP2A subfamily appears to be phylogenetically closest to the CYP2G subfamily.
Exon-Intron Structure of CYP2G2. To determine the exon-intron structure of cynomolgus monkey CYP2G2, we used the BLAT to align the cynomolgus monkey CYP2G2 cDNA sequence with the rhesus monkey (a closely related species of cynomolgus monkey) genome sequence. The analysis showed that cynomolgus monkey DPKYFCHPDD FYPQHFLDEQ GRFKKNEAFV PFSSGKRICL GEAMARMELF LYFTSILQNF SLHPLVPPVN IDITPKISGF GNIPPTYELC LIAR ***** * ********** ****** *** ****** * *** ***** ***** ** * * **** * * * *** ***** **** ** FIG. 1. Multiple alignment of CYP2G amino acid sequences in human, cynomolgus monkey, rabbit, rat, and mouse. Amino acid sequences were postulated from the human (h) CYP2G2P sequence found in the genome and deduced from the cynomolgus monkey (mf) CYP2G2 cDNA sequence. Rabbit (rab), rat (r), and mouse (m) CYP2G1 amino acid sequences were found in GenBank. These amino acid sequences were aligned using ClustalW. The hyphen (-) in the human CYP2G2P sequence indicates the nonsense mutation. The solid and broken lines above the sequences indicate the putative substrate recognition site (SRS) and heme-binding region, respectively. ‫,ء‬ Identical amino acids. * The genomic sequence corresponding to cynomolgus monkey CYP2G2 cDNA was used as the nucleotide sequence for comparison. For human CYP2G2P, the amino acid sequence deduced from this nucleotide sequence, without premature stop codons, was used for comparison.
IDENTIFICATION AND CHARACTERIZATION OF MACAQUE CYP2G2
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CYP2G2 was composed of nine exons, similar to mouse Cyp2g1, and the sizes of exons and introns ranged from 142 to Ͼ299 bp and from 110 to Ͼ2707 bp, respectively ( Table 2) . Some of the introns contained gaps in the sequences, and the entire sequence of the 3Ј-UTR has not been determined. All of the introns were bordered by typical consensus splice junctions (5Ј-GU and AG-3Ј).
Expression of CYP2G2 mRNA in Cynomolgus Monkey Tissues. Expression of cynomolgus monkey CYP2G2 mRNA was measured in the brain, lung, heart, liver, kidney, adrenal gland, jejunum, testis, ovary, uterus, and nasal mucosa by real-time RT-PCR using genespecific primers and probes. Among these tissues, cynomolgus monkey CYP2G2 mRNA was predominantly expressed in nasal mucosa, followed by testis and uterus in which the expression levels were substantially lower than in nasal mucosa (Fig. 3) . CYP2G2 mRNA was expressed only minimally in liver at approximately 1/1250 of the level in nasal mucosa.
Drug-Metabolizing Capability of CYP2G2 Protein. To determine whether cynomolgus monkey CYP2G2 protein heterologously expressed in E. coli is functional, metabolic assays were carried out using coumarin and progesterone as probe substrates. Cynomolgus monkey CYP2G2 catalyzed coumarin 7-hydroxylation (0.071 nmol per min/nmol P450) (Table 3) but at a lower rate than cynomolgus monkey CYP2A23 (0.62 nmol per min/nmol P450), CYP2A24 (6.94 nmol per min/nmol P450), or CYP2A26 (2.09 nmol per min/nmol P450) under the present conditions. Cynomolgus monkey CYP2G2 also metabolized progesterone at positions 6, 16, and 21 (Table 3) . Hydroxylation of coumarin and progesterone was also detected in cynomolgus monkey liver and nasal mucosa microsomes. These results indicate that cynomolgus monkey CYP2G2 protein is indeed a functional drug-metabolizing enzyme.
Expression of CYP2G2 in Nasal Mucosa. To investigate whether CYP2G2 protein is expressed in nasal mucosa, Western blot analysis was performed using a peptide antibody raised against cynomolgus monkey CYP2G2. To analyze the specificity of the antibody, recombinant cynomolgus monkey CYP2A23, CYP2A24, CYP2A26, and mfCYP2G2  hCYP2G2P  mfCYP2A24  mfCYP2A26  hCYP2A6  hCYP2A13  mfCYP2A23  hCYP2A7  mfCYP2C18 mfCYP2C18  hCYP2C18  mfCYP2C43  mfCYP2C75  hCYP2C9  hCYP2C19  mfCYP2C20  hCYP2C8  mfCYP2C76  mfCYP2E1  hCYP2E1 hCYP2E1  hCYP2F1  mfCYP2B6  hCYP2B6  hCYP2S1  hCYP2W1  mfCYP2D17  hCYP2D6  mfCYP2D44  mfCYP2J2  hCYP2J2 Real-time RT-PCR was performed with the primers and probe specific for CYP2G2 mRNA using the RT products generated from total RNA of brain, lung, heart, liver, kidney, adrenal gland, jejunum, testis, ovary, uterus, and nasal mucosa. Expression level of each mRNA was normalized to 18S rRNA level and represents the average Ϯ S.D. from three independent amplifications. For graphic representation, the expression level in nasal mucosa was adjusted to 1, with which all other values were compared.
TABLE 2

Exon-intron boundary sequences of cynomolgus monkey CYP2G2
Exon and intron sequences are indicated in capital and small letters, respectively. The dinucleotide sequences at the highly conserved GU-AG motif are shown as underlined bold letters. Exon-intron structure was determined by aligning cynomolgus monkey CYP2G2 cDNA sequence with the rhesus monkey genome sequence using BLAT. Because the genome assembly has not been completed in the part of intron 2 and intron 6, and the entire sequence of 3Ј-UTR has not been determined, precise sizes are not known for intron 2, intron 6, and exon 9. 
Drug-metabolizing activity of cynomolgus monkey CYP2G2 protein
Reactions were carried out using 50 M coumarin or 200 M progesterone, and 5 pmol cynomolgus monkey P450 protein or 0.1 mg/ml cynomolgus monkey nasal or liver microsomes as described under Materials and Methods. CYP2G2 proteins were included, in addition to cynomolgus monkey nasal mucosa microsomes, because cross-reactivity of mouse CYP2A5 antibody with mouse CYP2G1 has been observed . A single band (approximately 50 kDa) was detected with cynomolgus monkey CYP2G2, CYP2A23, CYP2A24, and CYP2A26 samples as well as in nasal mucosa microsomes (Fig. 4A) . Crossreactivity of the CYP2G2 antibody with CYP2A proteins prompted us to determine expression of CYP2A proteins in nasal mucosa microsomes. Western blot using human CYP2A6 antibody, which reacted with cynomolgus monkey CYP2A23, CYP2A24, and CYP2A26, but not with CYP2G2, did not show an appreciable signal in nasal mucosa (Fig. 4B ), indicating that CYP2A proteins were not expressed in the nasal mucosa at detectable levels. These results indicated that the band reacted with the CYP2G2 antibody corresponded to the CYP2G2 protein, suggesting that CYP2G2 is expressed as a protein in cynomolgus monkey nasal mucosa. Genotyping. To determine whether some animals possess nonsense mutations (c.76CϾT in exon 1 and c.382CϾT in exon 3) similar to those found in human CYP2G2P, CYP2G2 exons 1 and 3 were sequenced for 40 cynomolgus monkeys (20 Indochinese and 20 Indonesian) and 22 rhesus monkeys. Among the animals successfully genotyped, only three animals (two Indonesian cynomolgus monkeys and one rhesus monkey) possessed c.76CϾT (heterozygotes), whereas no animals carried c.382CϾT (Table 4) . A representative sequence chromatogram for each allele is described in Fig. 5 . The allele frequencies calculated from these data were 0.050 and 0.045 in Indonesian cynomolgus monkeys and rhesus monkeys, respectively, for c.76CϾT. None of the animals analyzed carried other nonsense mutations or deleterious mutations in exons 1 or 3, suggesting that CYP2G2 is most likely to be functional in all the animals analyzed.
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Discussion
Human CYP2G2P is a pseudogene, containing two nonsense mutations in the putative coding region (Sheng et al., 2000) and thus would not be functional even if expressed as mRNA. Analysis of the rhesus monkey genome data indicated that CYP2G2 contained a complete gene sequence, unlike human, apparently without the deleterious mutations in the putative coding region. On the basis of this sequence, in this study, we isolated CYP2G2 cDNA from cynomolgus monkey nasal mucosa. Cynomolgus monkey CYP2G2 cDNA was highly identical to human CYP2G2P and mouse CYP2G1 cDNA and contained an ORF with primary structures characteristic of P450 proteins, including the heme-binding region.
Of the 11 tissues examined in this study, cynomolgus monkey CYP2G2 mRNA was expressed predominantly in nasal mucosa. Likewise, mouse, rat, and rabbit CYP2G1 mRNAs have been reported to be expressed predominantly in nasal mucosa (Nef et al., 1989; Ding et al., 1991; Hua et al., 1997) . Such predominant expression suggests that CYP2G has a possible important function in the nasal mucosa. Mouse CYP2G1 has been shown to metabolize exogenous compounds, including coumarin, 2,6-dichlorobenzonitrile, and acetaminophen Zhuo et al., 1999) , which results in tissueselective toxicity in the nasal mucosa (Brandt et al., 1990; Gu et al., 1997; Genter et al., 1998) . In this study, cynomolgus monkey CYP2G2 metabolized coumarin and progesterone. Moreover, mouse and rabbit CYP2G1 have been reported to metabolize progesterone (Ding and Coon, 1994; Hua et al., 1997) , indicating that cynomolgus monkey CYP2G2 shares metabolic properties with mouse and rabbit CYP2G enzymes. Therefore, cynomolgus monkey CYP2G2 might function similarly to mouse and rabbit CYP2G1 by activating some exogenous compounds. Metabolic assays could be performed using the cynomolgus monkey CYP2G2 protein and above compounds to investigate this finding in the future.
The polyclonal antibody raised against cynomolgus monkey CYP2G2 reacted with cynomolgus monkey CYP2A23, CYP2A24, and CYP2A26. Likewise, a previous study showed cross-reactivity between mouse CYP2G1 and CYP2A5 using anti-CYP2A5 antibody, likely reflecting the sequence similarity of CYP2G and CYP2A proteins, as shown by phylogenetic analysis. This result might partly account for the functional properties (coumarin 7-hydroxylation) shared by cynomolgus monkey CYP2G and CYP2A proteins. Human CYP2A13 is expressed at its highest level in the nasal mucosa and metabolizes various exogenous toxicants (Su et al., 2000) . In this study, cynomolgus monkey CYP2A proteins were not detected in the nasal mucosa. Because CYP2G shares functional properties with CYP2A, CYP2G2 instead of CYP2A might play similar roles as human CYP2A13 in cynomolgus monkey nasal mucosa. However, substrates metabolized solely by CYP2G2, if any, could cause the differences of drug metabolism and toxicity in the nasal mucosa between cynomolgus monkeys and humans. Species difference is a major issue in preclinical studies, because the data obtained using animals must be extrapolated to humans. Recombinant cynomolgus monkey CYP2G2 protein would be useful in investigations of such species differences. Human CYP2G2P contained two nonsense mutations in the putative coding region, c.76CϾT in exon 1 and c.382CϾT in exon 3 (Sheng et al., 2000) . The cynomolgus monkeys and rhesus monkeys analyzed in this study were not homozygous for mutations corresponding to these human CYP2G2P nonsense mutations. Two of the 20 Indonesian cynomolgus monkeys and 1 of the 11 rhesus monkeys were heterozygous for c.76CϾT, whereas none of the 19 Indochinese cynomolgus monkeys possessed this allele. None of the animals possessed c.382CϾT. These results suggest that most cynomolgus monkeys and rhesus monkeys possess a functional CYP2G2 protein, although rhesus monkey CYP2G2 cDNA was not isolated in this study because of the unavailability of the tissue samples. Because there are only two nonsense mutations in human CYP2G2P, it is possible that a functional CYP2G2P is expressed in some individuals with concomitant mutations at the sites of these nonsense mutations. Alternatively, gene conversion and unequal crossover of CYP2G1P and CYP2G2P could give rise to a functional CYP2G transcript. Macaques might be suitable for investigation of CYP2G2-dependent drug metabolism in humans.
Another human CYP2G, CYP2G1P, a pseudogene highly identical to CYP2G2P, is present in the genome (Sheng et al., 2000) . Human CYP2G1P contained a large deletion in the putative exon 4 -6 and 1-base deletion in the putative exon 2 (Sheng et al., 2000) . Two macaque CYP2Gs, in addition to CYP2G2, are present in the genome (Hoffman and Hu, 2007) . These macaque CYP2Gs, CYP2G17P and CYP2G18P, named by the P450 Nomenclature Committee (http:// drnelson.uthsc.edu/cytochromeP450.html), shared high sequence identity with both human CYP2G1P and CYP2G2P (Y. Uno, unpublished data). CYP2G17P and CYP2G18P are pseudogenes, because CYP2G17P contained several nonsense mutations and CYP2G18P lacked some exons, in their gene sequences (Hoffman and Hu, 2007) . These results suggest that CYP2G2 is probably only a functional gene in macaques, although we cannot exclude the possibility that additional CYP2G gene(s) are present in the gaps of the genome assembly.
In macaque, cattle, rabbit, rat, and mouse, CYP2G appears to be expressed and to encode a functional protein but is pseudogenized in human. Other mammalian species also possess CYP2G sequence in their genomes, including primates (chimpanzee, orangutan, and marmoset), whereas CYP2G-like sequences do not appear to be present in some bird or fish genomes (Y. Uno, unpublished data). It remains to be determined whether these CYP2G sequences found in the genomes (of other mammalian species) are expressed and encode a functional protein. CYP2Gs are absent or pseudogenized in the genomes of some species, indicating that CYP2G function is needed in a speciesdependent manner. In other species, other P450s might play roles similar to CYP2G, as discussed above.
In conclusion, we identified cynomolgus monkey CYP2G2 cDNA, highly identical to human CYP2G2P. Of 11 tissues analyzed, cynomolgus monkey CYP2G2 mRNA was predominantly expressed in the nasal mucosa. Cynomolgus monkey CYP2G2 protein was expressed in the nasal mucosa and metabolized coumarin, indicating that CYP2G2 is a functional drug-metabolizing enzyme. None of the cynomolgus and rhesus monkeys analyzed was homozygous for the nonsense mutations corresponding to those found in human CYP2G2P. These results suggest that cynomolgus monkey CYP2G2 is a drug-metabolizing enzyme, which could play functional roles in the nasal mucosa.
